Forum: Genfit » DSMB approves

Met IEX wordt u een betere belegger en verhoogt u het rendement op uw beleggingen

Vanaf 13,95 per maand leest u dagelijks onze professionele aandelenanalyses en kooptips.

Krijg toegang tot vele voordelen

Onbeperkt toegang tot onze Premium-content
Ons magazine IEX Expert (digitaal of papier)
Toegang tot onze 3 modelportefeuilles

Profiteer van de IEX producten

3 Modelportefeuilles
Dividendkalender
Aandelenselector

Aandeel Genfit PSE:GNFT.FR, FR0004163111

Laatste koers (eur) 3,240 2 mei 2024 17:35

Verschil +0,040 (+1,25%) Dagrange 3,195 - 3,235

Volume 31.087 Gem. (3M) 115,4K

Opstapelen 25 oktober 2013 18:09

Hoppa, riemen vast maandag, unrestricted approve!

genfit.com/fileadmin/press/press/pres...

The independent Data Safety Monitoring Board (DSMB) of international experts, after analyzing the safety data for GFT505 in the ongoing Phase IIb clinical trial, unanimously recommends continuing the study according to the planned protocol
Lille (France), Boston (Massachusetts, United States), October 25, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces the recommendation of the independent Data Safety and Monitoring Board (DSMB) of international experts charged with ensuring the safety of use of GFT505 in the current Phase IIb study. The DSMB gives its unrestricted approval to continue the Phase IIb clinical trial in NASH according to the planned protocol.
GENFIT launched the Phase IIb study of GFT505 in NASH in September 2012, after obtaining FDA (Food and Drug Administration) approval to perform the study in the United States. To date the study has recruited 139 diabetic and non-diabetic patients with a histological diagnosis of NASH by liver biopsy at the time of recruitment. The study is currently ongoing in Europe and the United States in 56 clinical investigation centers.
The members of the DSMB, an independent committee set up to ensure patient safety within the Phase IIb study, analyzed the complete safety data for patients that have been treated for more than 6 months with GFT505 at 80 mg/day.
The members of the DSMB unanimously concluded that, after more than 6 months of treatment at the dose of 80 mg/day, GFT505 shows no safety issue that compromises the continuation of the Phase IIb study.
Jean-François MOUNEY, Chairman and Chief Executive Officer of GENFIT, declared: « We are extremely pleased with this decision that marks a much-awaited key step in this study, and further adds to the potential value of our drug candidate. Indeed the DSMB has given its unrestricted approval to move to the higher dose of GFT505, and recommends the continuation of the study according to the planned protocol. Consequently, the next patients that are randomized to receive GFT505 in the trial will be treated at 120 mg/day for 12 months. »

Direct naar Forum

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Beurscodes, betekenis en hulp bij zoeken

Europa

Noord-Amerika

Kunt u een instrument niet vinden?

Waar vind ik die ISIN code?

Inloggen

Met IEX wordt u een betere belegger en verhoogt u het rendement op uw beleggingen

Krijg toegang tot vele voordelen

Profiteer van de IEX producten

Nederland

Europa

Amerika

Aandeel Genfit PSE:GNFT.FR, FR0004163111

Melding

DSMB approves

Opstapelen

Aanbevelingen

Aantal posts: 4.886

Opstapelen

Aanbevelingen

Aantal posts: 4.886

[verwijderd]

Aanbevelingen

Aantal posts: 0

Meedoen aan de discussie?

Direct naar Forum

Benieuwd naar onze analyses en kooptips?

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Nederlandse MKB Participatiemaatschappij

Bitvavo

MeManaged vermogensbeheer

Hét Warren Buffett-pakket al aangevraagd?

Pearl Capital: beleggen met zekerheid

Meld u aan voor de dagelijkse Beursupdate

Verzoek